An actual-world research of sufferers with mantle mobile lymphoma (MCL) handled with Bruton tyrosine kinase (BTK) inhibitors at network oncology practices in the USA suggests remedy length and adherence was once upper amongst sufferers receiving zanubrutinib when compared with acalabrutinib or ibrutinib.
The findings have been printed in a topic complement within the Magazine of Medical Oncology, a newsletter of the American Society of Medical Oncology (ASCO), that includes abstracts from the ASCO Annual Assembly. The find out about was once carried out to offer perception into real-world BTK inhibitor remedy patterns in MCL, as present knowledge are restricted.
The retrospective, observational find out about integrated a complete of 402 sufferers with MCL handled with BTK inhibitors in step with digital scientific file (EMR) knowledge from 18 network oncology practices. EMR knowledge integrated scientific historical past and no less than 6 months of follow-up, with index date outlined by means of any of the three BTK inhibitors integrated within the find out about. EMR and claims knowledge during the finish of follow-up have been used to calculate remedy length.
Some of the general inhabitants, 44 sufferers have been handled with zanubrutinib, 161 acalabrutinib, and 197 ibrutinib. The median (vary) affected person age was once 75 (56-89) years within the zanubrutinib workforce, 76 (36-89) years within the acalabrutinib workforce, and 72 (36-89) years within the ibrutinib workforce. With the exception of age, the three teams have been identical in the case of baseline traits.
The researchers discovered that part of the sufferers within the zanubrutinib workforce had gained different BTK inhibitors in earlier strains of remedy. Additional, 31.8% switched to zanubrutinib from different BTK inhibitors inside 60 days of remedy initiation. Amongst the ones handled with acalabrutinib, 29% have been handled with different BTK inhibitors in prior strains of remedy.
Imply follow-up sessions have been 493 days within the zanubrutinib workforce, 701 days within the acalabrutinib workforce, and 746 days within the ibrutinib workforce. The authors famous that the zanubrutinib workforce’s shorter follow-up time was once because of a later approval date vs the opposite treatments.
In spite of a shorter follow-up duration, sufferers who gained zanubrutinib had longer median remedy length than each the acalabrutinib and ibrutinib teams (292 days, 259 days, and 149 days, respectively; P < .01).
“Actual-world EMR knowledge from US community-based oncology practices steered considerably longer remedy length and adherence in MCL sufferers handled with zanubrutinib when compared with acalabrutinib or ibrutinib,” the authors concluded. “Additional analyses on long-term usage are wanted upon knowledge maturation.”
Reference
Shah BD, Xue M, Yang Ok, Liu S, Tang B. Actual-world remedy patterns of Bruton tyrosine kinase inhibitors (BTKi) in sufferers with mantle mobile lymphoma (MCL) in network oncology practices in the USA (US). J Clin Oncol. 2023;41(suppl 16):e19525. doi:10.1200/JCO.2023.41.16_suppl.e19525
